ArticleBiomolecules & biomedicine2025
Machine learning integration of single-cell and bulk transcriptomics identifies fibroblast-driven prognostic markers in colorectal cancer.
Article in Biomolecules & biomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Single-cell RNA sequencing (scRNA-seq) has significantly advanced our understanding of cellular heterogeneity and the complex interplay within the tumor microenvironment (TME) of colorectal cancer (CRC). However, translating these molecular insights into clinically actionable prognostic biomarkers and therapeutic strategies remains a considerable challenge. In this study, we conducted a comprehensive scRNA-seq analysis of 306 CRC samples comprising 448,255 cells to characterize the TME in depth. By constructing intercellular communication networks based on connection counts and communication probabilities, we identified fibroblasts as central regulatory hubs within the TME. Using Wilcoxon rank-sum tests and univariate survival analyses, we initially identified 23 prognostic fibroblast markers. These were refined to a seven-gene fibroblast-related prognostic signature via an integrated machine learning approach. The signature exhibited robust predictive performance in the The Cancer Genome Atlas - Colon Adenocarcinoma (TCGA-COAD) training cohort (n=351; C-index=0.65) and was successfully validated in the GSE17536 dataset (n=177; C-index=0.63). Functional enrichment analyses revealed that this signature is involved in immune regulation and multiple tumor-associated cellular pathways. Notably, high-risk patients displayed increased macrophage and NK cell infiltration, impaired immune function, and elevated immune rejection scores, while low-risk patients demonstrated heightened sensitivity to camptothecin and irinotecan. Together, our findings underscore the prognostic value of fibroblast-derived signatures in CRC and support their potential utility in risk stratification and the development of personalized therapeutic strategies, contributing to the advancement of precision oncology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.